These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 22356665)

  • 1. Effect of buprenorphine dose on treatment outcome.
    Fareed A; Vayalapalli S; Casarella J; Drexler K
    J Addict Dis; 2012; 31(1):8-18. PubMed ID: 22356665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.
    Marsch LA; Bickel WK; Badger GJ; Stothart ME; Quesnel KJ; Stanger C; Brooklyn J
    Arch Gen Psychiatry; 2005 Oct; 62(10):1157-64. PubMed ID: 16203961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid detoxification using high doses of buprenorphine in 24 hours: a randomized, double blind, controlled clinical trial.
    Assadi SM; Hafezi M; Mokri A; Razzaghi EM; Ghaeli P
    J Subst Abuse Treat; 2004 Jul; 27(1):75-82. PubMed ID: 15223097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Buprenorphine treatment for opioid dependence: the relative efficacy of daily, twice and thrice weekly dosing.
    Marsch LA; Bickel WK; Badger GJ; Jacobs EA
    Drug Alcohol Depend; 2005 Feb; 77(2):195-204. PubMed ID: 15664721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs. methadone.
    Seifert J; Metzner C; Paetzold W; Borsutzky M; Passie T; Rollnik J; Wiese B; Emrich HM; Schneider U
    Pharmacopsychiatry; 2002 Sep; 35(5):159-64. PubMed ID: 12237786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mood and affect during detoxification of opiate addicts: a comparison of buprenorphine versus methadone.
    Seifert J; Metzner C; Paetzold W; Borsutzky M; Ohlmeier M; Passie T; Hauser U; Becker H; Wiese B; Emrich H; Schneider U
    Addict Biol; 2005 Jun; 10(2):157-64. PubMed ID: 16191668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of a Payer-Mandated Decrease in Buprenorphine Dose on Aberrant Drug Tests and Treatment Retention Among Patients with Opioid Dependence.
    Accurso AJ; Rastegar DA
    J Subst Abuse Treat; 2016 Feb; 61():74-9. PubMed ID: 26639639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial.
    Wedam EF; Bigelow GE; Johnson RE; Nuzzo PA; Haigney MC
    Arch Intern Med; 2007 Dec; 167(22):2469-75. PubMed ID: 18071169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of an injection depot formulation of buprenorphine: placebo comparison.
    Sigmon SC; Wong CJ; Chausmer AL; Liebson IA; Bigelow GE
    Addiction; 2004 Nov; 99(11):1439-49. PubMed ID: 15500597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic response in outpatient opioid substitution treatment].
    Barisić V; Barisić Z
    Acta Med Croatica; 2009 Oct; 63(4):279-83. PubMed ID: 20034328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A dose-effect study of repeated administration of buprenorphine/naloxone on performance in opioid-dependent volunteers.
    Mintzer MZ; Correia CJ; Strain EC
    Drug Alcohol Depend; 2004 May; 74(2):205-9. PubMed ID: 15099664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Buprenorphine transdermal delivery system in adults with persistent noncancer-related pain syndromes who require opioid therapy: a multicenter, 5-week run-in and randomized, double-blind maintenance-of-analgesia study.
    Landau CJ; Carr WD; Razzetti AJ; Sessler NE; Munera C; Ripa SR
    Clin Ther; 2007 Oct; 29(10):2179-93. PubMed ID: 18042474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse.
    Schottenfeld RS; Pakes JR; Oliveto A; Ziedonis D; Kosten TR
    Arch Gen Psychiatry; 1997 Aug; 54(8):713-20. PubMed ID: 9283506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Buprenorphine and methadone to opiate addicts--a randomized trial].
    Kristensen Ø; Espegren O; Asland R; Jakobsen E; Lie Ø; Seiler S
    Tidsskr Nor Laegeforen; 2005 Jan; 125(2):148-51. PubMed ID: 15665884
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buprenorphine tablet versus liquid: a clinical trial comparing plasma levels, efficacy, and symptoms.
    Chawarski MC; Moody DE; Pakes J; O'Connor PG; Schottenfeld RS
    J Subst Abuse Treat; 2005 Dec; 29(4):307-12. PubMed ID: 16311183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone.
    Fudala PJ; Bridge TP; Herbert S; Williford WO; Chiang CN; Jones K; Collins J; Raisch D; Casadonte P; Goldsmith RJ; Ling W; Malkerneker U; McNicholas L; Renner J; Stine S; Tusel D;
    N Engl J Med; 2003 Sep; 349(10):949-58. PubMed ID: 12954743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment outcome for flexible dosing buprenorphine maintenance treatment.
    Fareed A; Vayalapalli S; Casarella J; Drexler K
    Am J Drug Alcohol Abuse; 2012 Mar; 38(2):155-60. PubMed ID: 22175698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of four buprenorphine dosing regimens in the treatment of opioid dependence.
    Petry NM; Bickel WK; Badger GJ
    Clin Pharmacol Ther; 1999 Sep; 66(3):306-14. PubMed ID: 10511067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment retention in adolescent patients treated with methadone or buprenorphine for opioid dependence: a file review.
    Bell J; Mutch C
    Drug Alcohol Rev; 2006 Mar; 25(2):167-71. PubMed ID: 16627307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New drugs for substitution treatment of opioid dependence. Buprenorphine and 1-alpha-acetylmethadol (LAAM) ].
    Petersen H; Skauge L; Svejsø J; Ege PP
    Ugeskr Laeger; 2000 Nov; 162(48):6553-6. PubMed ID: 11187226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.